The Antigen ASB4 on Cancer Stem Cells Serves as a Target for CTL Immunotherapy of Colorectal Cancer.

abstract：:A posteriori evidence suggests that radiotherapy to a targeted tumor can elicit an immune-mediated abscopal (ab-scopus, away from the target) effect in non-targeted tumors, when combined with an anti-cytotoxic T-lymphocyte antigen-4 monoclonal (CTLA-4) antibody. Concurrent radiotherapy and ipilimumab (a human monoclon...

journal_title：Cancer immunology research

authors： Golden EB,Demaria S,Schiff PB,Chachoua A,Formenti SC

更新日期：2013-12-01 00:00:00

abstract：:The prognosis is very dismal for patients with relapsed CD20(+) B-cell non-Hodgkin lymphoma (B-NHL). Facilitating the development of alternative novel therapeutic strategies is required to improve outcomes in patients with recurrent/refractory CD20(+) B-NHL. In this study, we investigated functional activities of anti...

journal_title：Cancer immunology research

authors： Chu Y,Hochberg J,Yahr A,Ayello J,van de Ven C,Barth M,Czuczman M,Cairo MS

更新日期：2015-04-01 00:00:00

abstract：:Recruitment of myeloid-derived suppressor cells (MDSC) into the tumor microenvironment (TME) contributes to cancer immune evasion. MDSCs express the chemokine receptor CXCR2, and inhibiting CXCR2 suppresses the recruitment of MDSCs into the tumor and the premetastatic niche. Here, we compared the growth and metastasis...

journal_title：Cancer immunology research

authors： Yang J,Yan C,Vilgelm AE,Chen SC,Ayers GD,Johnson CA,Richmond A

更新日期：2020-11-11 00:00:00

abstract：:New immunotherapeutic strategies are needed to induce effective antitumor immunity in all cancer patients. Malignant mesothelioma is characterized by a poor prognosis and resistance to conventional therapies. Infiltration of tumor-associated macrophages (TAM) is prominent in mesothelioma and is linked to immune suppre...

journal_title：Cancer immunology research

authors： Dammeijer F,Lievense LA,Kaijen-Lambers ME,van Nimwegen M,Bezemer K,Hegmans JP,van Hall T,Hendriks RW,Aerts JG

更新日期：2017-07-01 00:00:00

abstract：:Anti-Programed Death 1 (PD-1) is standard immunotherapy for multiple cancers, and the expression of one of its ligands, PD-L1, has been described in germ cell tumors (GCT). Neither the clinical activity of anti-PD-1 nor the incidence of an immunoresponsive tumor microenvironment has been described for GCTs. A patient ...

journal_title：Cancer immunology research

authors： Shah S,Ward JE,Bao R,Hall CR,Brockstein BE,Luke JJ

更新日期：2016-11-01 00:00:00

abstract：:Hypoxia-driven, A2A adenosine receptor (A2AR)-mediated (hypoxia-A2-adenosinergic), T-cell-autonomous immunosuppression was first recognized as critical and nonredundant in protecting normal tissues from inflammatory damage and autoimmunity. However, this immunosuppressive mechanism can be highjacked by bacteria and tu...

journal_title：Cancer immunology research

authors： Sitkovsky MV,Hatfield S,Abbott R,Belikoff B,Lukashev D,Ohta A

更新日期：2014-07-01 00:00:00

abstract：:One limiting factor of CAR T-cell therapy for treatment of solid cancers is the suppressive tumor microenvironment (TME), which inactivates the function of tumor-infiltrating lymphocytes (TIL) through the production of immunosuppressive molecules, such as adenosine. Adenosine inhibits the function of CD4+ and CD8+ T c...

journal_title：Cancer immunology research

authors： Siriwon N,Kim YJ,Siegler E,Chen X,Rohrs JA,Liu Y,Wang P

更新日期：2018-07-01 00:00:00

abstract：:Chronic inflammation drives colitis-associated colorectal cancer (CAC) in inflammatory bowel disease (IBD). FoxP3+ regulatory T cells (Treg) coexpressing the Th17-related transcription factor RORγt accumulate in the lamina propria of IBD patients, where they are thought to represent an intermediate stage of developmen...

journal_title：Cancer immunology research

authors： Rizzo A,Di Giovangiulio M,Stolfi C,Franzè E,Fehling HJ,Carsetti R,Giorda E,Colantoni A,Ortenzi A,Rugge M,Mescoli C,Monteleone G,Fantini MC

更新日期：2018-09-01 00:00:00

abstract：:Targeted monoclonal antibody therapy is a promising therapeutic strategy for cancer, and antibody-dependent cell-mediated cytotoxicity (ADCC) represents a crucial mechanism underlying these approaches. The majority of patients have limited responses to monoclonal antibody therapy due to the development of resistance. ...

journal_title：Cancer immunology research

authors： Aldeghaither DS,Zahavi DJ,Murray JC,Fertig EJ,Graham GT,Zhang YW,O'Connell A,Ma J,Jablonski SA,Weiner LM

更新日期：2019-02-01 00:00:00

abstract：:Proneural-to-mesenchymal transition (PMT) is a common process in glioblastoma (GBM) progression that leads to increased radiotherapy resistance. However, the mechanism underlying PMT is poorly understood. Here, we found that tumor-associated macrophages triggered PMT in glioma stem cells (GSC) via small extracellular ...

journal_title：Cancer immunology research

authors： Zhang Z,Xu J,Chen Z,Wang H,Xue H,Yang C,Guo Q,Qi Y,Guo X,Qian M,Wang S,Qiu W,Gao X,Zhao R,Guo X,Li G

更新日期：2020-07-01 00:00:00

abstract：:Radiotherapy (RT) represents one of the main anticancer approaches for the treatment of solid tumors. Beyond the expected direct effects of RT on tumor cells, evidence supporting the importance of an immune response to RT is growing. The balance between RT-mediated immunogenic and tolerogenic activity is ill-defined a...

journal_title：Cancer immunology research

authors： Mondini M,Loyher PL,Hamon P,Gerbé de Thoré M,Laviron M,Berthelot K,Clémenson C,Salomon BL,Combadière C,Deutsch E,Boissonnas A

更新日期：2019-03-01 00:00:00

abstract：:The relationship between the adaptive CD4+ T cell response and human cancer is unclear. The oncofetal antigen 5T4 is expressed on many human carcinomas, including colorectal cancer (CRC) cells, but has limited expression on normal tissues. We previously identified anti-5T4 CD4+ T cells in a proportion of CRC patients,...

journal_title：Cancer immunology research

authors： Scurr M,Bloom A,Pembroke T,Srinivasan R,Brown C,Smart K,Bridgeman H,Davies M,Hargest R,Phillips S,Christian A,Hockey T,Gallimore A,Godkin A

更新日期：2013-12-01 00:00:00

abstract：:Immunotherapies targeting T lymphocytes are revolutionizing cancer therapy but only benefit a subset of patients, especially in colorectal cancer. Thus, additional insight into the tumor microenvironment (TME) is required. Eosinophils are bone marrow-derived cells that have been largely studied in the context of aller...

journal_title：Cancer immunology research

authors： Reichman H,Itan M,Rozenberg P,Yarmolovski T,Brazowski E,Varol C,Gluck N,Shapira S,Arber N,Qimron U,Karo-Atar D,Lee JJ,Munitz A

更新日期：2019-03-01 00:00:00

abstract：:We assessed the contribution of IL1 signaling molecules to malignant tumor growth using IL1β-/-, IL1α-/-, and IL1R1-/- mice. Tumors grew progressively in IL1R-/- and IL1α-/- mice but were often absent in IL1β-/- mice. This was observed whether tumors were implanted intradermally or injected intravenously and was true ...

journal_title：Cancer immunology research

authors： Tian T,Lofftus S,Pan Y,Stingley CA,King SL,Zhao J,Pan TY,Lock R,Marglous JW,Liu K,Widlund HR,Fuhlbrigge RC,Cichowski K,Kupper TS

更新日期：2020-05-01 00:00:00

abstract：:Tertiary lymphoid structures (TLS) are ectopic lymphoid aggregates that phenotypically resemble conventional secondary lymphoid organs and are commonly found at sites of chronic inflammation. They are also found in a wide variety of primary and metastatic human tumors. The presence of tumor-associated TLS (TA-TLS) is ...

journal_title：Cancer immunology research

authors： Rodriguez AB,Engelhard VH

更新日期：2020-11-01 00:00:00

abstract：:CD169 (sialoadhesin) is a sialic acid receptor that is specifically expressed on macrophages, including lymph node sinus macrophages. Animal studies suggest that CD169(+) macrophages in lymph nodes have properties in preventing cancers. In order to determine the significance of CD169(+) macrophages in patients with ma...

journal_title：Cancer immunology research

authors： Saito Y,Ohnishi K,Miyashita A,Nakahara S,Fujiwara Y,Horlad H,Motoshima T,Fukushima S,Jinnin M,Ihn H,Takeya M,Komohara Y

更新日期：2015-12-01 00:00:00

abstract：:The TNF receptor family member OX40 promotes activation and proliferation of T cells, which fuels efforts to modulate this immune checkpoint to reinforce antitumor immunity. Besides T cells, NK cells are a second cytotoxic lymphocyte subset that contributes to antitumor immunity, particularly in leukemia. Accordingly,...

journal_title：Cancer immunology research

authors： Nuebling T,Schumacher CE,Hofmann M,Hagelstein I,Schmiedel BJ,Maurer S,Federmann B,Rothfelder K,Roerden M,Dörfel D,Schneider P,Jung G,Salih HR

更新日期：2018-02-01 00:00:00

abstract：:Multiple myeloma is characterized by the clonal expansion of malignant plasma cells in the bone marrow. But the phenotypic diversity and the contribution of less predominant B-lineage clones to the biology of this disease have been controversial. Here, we asked whether cells bearing the dominant multiple myeloma immun...

journal_title：Cancer immunology research

authors： Hansmann L,Han A,Penter L,Liedtke M,Davis MM

更新日期：2017-09-01 00:00:00

abstract：:In the past five decades, the role for lymphocytes in host immune response to tumors has been shown, at least in some patients, to be a critical component in disease prognosis. Also, the heterogeneity of lymphocytes has been documented, including the existence of regulatory T cells that suppress the immune response. A...

journal_title：Cancer immunology research

authors： Mihm MC Jr,Mulé JJ

更新日期：2015-08-01 00:00:00

abstract：:Antibody-drug conjugates (ADC) are emerging as powerful treatment strategies with outstanding target-specificity and high therapeutic activity in patients with cancer. Brentuximab vedotin represents a first-in-class ADC directed against CD30(+) malignancies. We hypothesized that its sustained clinical responses could ...

journal_title：Cancer immunology research

authors： Müller P,Martin K,Theurich S,Schreiner J,Savic S,Terszowski G,Lardinois D,Heinzelmann-Schwarz VA,Schlaak M,Kvasnicka HM,Spagnoli G,Dirnhofer S,Speiser DE,von Bergwelt-Baildon M,Zippelius A

更新日期：2014-08-01 00:00:00

abstract：:Immunotherapy with monoclonal antibodies targeting cytotoxic T-lymphocyte antigen 4 (CTLA-4) or programmed cell death 1 (PD-1) has improved the survival of patients with metastatic melanoma. These agents carry a certain risk of adverse immune-related events. We present a patient with widely metastatic melanoma who was...

journal_title：Cancer immunology research

authors： Maurice C,Schneider R,Kiehl TR,Bavi P,Roehrl MH,Mason WP,Hogg D

更新日期：2015-12-01 00:00:00

abstract：:Increased angiogenesis and tumor-induced immune evasion are two mechanisms by which clear cell renal cell carcinoma (ccRCC) proliferate and metastasize; however, the relationship between these pathways in human ccRCC is poorly understood. We conducted a nested case-control study using 98 archived tumor samples from pa...

journal_title：Cancer immunology research

authors： Joseph RW,Parasramka M,Eckel-Passow JE,Serie D,Wu K,Jiang L,Kalari K,Thompson RH,Huu Ho T,Castle EP,Cheville J,Kwon ED,Thompson EA,Parker A

更新日期：2013-12-01 00:00:00

abstract：:CD47-specific antibodies and fusion proteins that block CD47-SIRPα signaling are employed as antitumor agents for several cancers. Here, we investigated the synergistic antitumor effect of simultaneously targeting CD47 and autophagy in non-small cell lung cancer (NSCLC). SIRPαD1-Fc, a novel CD47-targeting fusion prote...

journal_title：Cancer immunology research

authors： Zhang X,Fan J,Wang S,Li Y,Wang Y,Li S,Luan J,Wang Z,Song P,Chen Q,Tian W,Ju D

更新日期：2017-05-01 00:00:00

abstract：:Ligation of GITR (glucocorticoid-induced tumor necrosis factor (TNF) receptor-related gene, or TNFRSF18) by agonist antibody has recently entered into early phase clinical trials for the treatment of advanced malignancies. Although the ability of GITR modulation to induce tumor regression is well-documented in preclin...

journal_title：Cancer immunology research

authors： Schaer DA,Budhu S,Liu C,Bryson C,Malandro N,Cohen A,Zhong H,Yang X,Houghton AN,Merghoub T,Wolchok JD

更新日期：2013-11-01 00:00:00

abstract：:Pancreatic ductal adenocarcinoma (PDAC) is the third leading cause of cancer death in the United States. Pancreatic tumors are minimally infiltrated by T cells and are largely refractory to immunotherapy. Accordingly, the role of T-cell immunity in pancreatic cancer has been somewhat overlooked. Here, we hypothesized ...

journal_title：Cancer immunology research

authors： Ajina R,Malchiodi ZX,Fitzgerald AA,Zuo A,Wang S,Moussa M,Cooper CJ,Shen Y,Johnson QR,Parks JM,Smith JC,Catalfamo M,Fertig EJ,Jablonski SA,Weiner LM

更新日期：2021-01-28 00:00:00

abstract：:Efficacious antitumor immune responses must overcome multiple suppressive mechanisms in the tumor microenvironment to control cancer progression. In this study, we demonstrate that dual targeting of suppressive myeloid populations by inhibiting CSF-1/CSF-1R signaling and activation of antigen-presenting cells with ago...

journal_title：Cancer immunology research

authors： Wiehagen KR,Girgis NM,Yamada DH,Smith AA,Chan SR,Grewal IS,Quigley M,Verona RI

更新日期：2017-12-01 00:00:00

abstract：:The goal of this study was to characterize the molecular mechanisms underlying cetuximab-mediated upregulation of HLA class I antigen-processing machinery components in head and neck cancer (HNC) cells and to determine the clinical significance of these changes in cetuximab-treated HNC patients. Flow cytometry, signal...

journal_title：Cancer immunology research

authors： Srivastava RM,Trivedi S,Concha-Benavente F,Hyun-Bae J,Wang L,Seethala RR,Branstetter BF 4th,Ferrone S,Ferris RL

更新日期：2015-08-01 00:00:00

abstract：:Pancreatic cancer is the fourth leading cause of cancer-related deaths in the United States. Less than 6% of patients survive beyond the fifth year due to inadequate early diagnostics and ineffective treatment options. Our laboratory has developed an allogeneic, granulocyte-macrophage colony-stimulating factor (GM-CSF...

journal_title：Cancer immunology research

authors： Jhaveri DT,Kim MS,Thompson ED,Huang L,Sharma R,Klein AP,Zheng L,Le DT,Laheru DA,Pandey A,Jaffee EM,Anders RA

更新日期：2016-03-01 00:00:00

abstract：:Although immune checkpoint blockade (ICB) improves clinical outcome in several types of malignancies, pancreatic ductal adenocarcinoma (PDA) remains refractory to this therapy. Preclinical studies have demonstrated that the relative abundance of suppressive myeloid cells versus cytotoxic T cells determines the efficac...

journal_title：Cancer immunology research

authors： Li J,Yuan S,Norgard RJ,Yan F,Yamazoe T,Blanco A,Stanger BZ

更新日期：2020-03-01 00:00:00

abstract：:Solid tumors are refractory to cellular immunotherapies in part because they contain suppressive immune effectors such as myeloid-derived suppressor cells (MDSCs) that inhibit cytotoxic lymphocytes. Strategies to reverse the suppressive tumor microenvironment (TME) should also attract and activate immune effectors wit...

journal_title：Cancer immunology research

authors： Parihar R,Rivas C,Huynh M,Omer B,Lapteva N,Metelitsa LS,Gottschalk SM,Rooney CM

更新日期：2019-03-01 00:00:00